Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's Laboratories enters into exclusive sales and distribution agreement with Novartis India Limited for select India brands"
This is for your information.
| /s/ Vivek Mittal | |
| Vivek Mittal | |
| Global General Counsel and Compliance Officer |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com | USHA IYER ushaiyer@drreddys.com |
Laboratories enters into exclusive sales and distribution agreement
with Novartis India Limited for select India brands
Hyderabad, India, February 11, 2022
- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy's")
today announced that it has entered into an exclusive sales and distribution agreement with Novartis India Limited ("NIL")
for the Voveran range, the Calcium range and Methergine in India.
Under the arrangement, Dr. Reddy's will
have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine
in India. The company will use its strengths in promotion and distribution to considerably expand its engagement with healthcare
professionals with the aim of enabling access to patients in need.
M.V. Ramana, CEO - Branded Markets
(India & Emerging Markets), said: "We are delighted to enter into this arrangement with NIL to promote and distribute
these well-established brands that are trusted by patients and healthcare professionals. Our India business has been a strong growth
driver and remains a key focus market for us. This arrangement will strengthen our portfolio in the pain management and women's
health areas. It is our endeavour to build on the legacy created by NIL over the years and we intend to evaluate capabilities to
maintain business continuity. This will help accelerate access and reach more patients in keeping with our purpose of Good
Health Can't Wait'."
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across
the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on
to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency
exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration
issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products
and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange
Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained